NEW YORK (GenomeWeb News) – Two investment banks today initiated coverage of Veracyte with Outperform ratings on the company's stock.

The coverage initiation by Cowen & Co., and Leerwink Swann follows Veracyte's announcement on Monday that revenues for its third quarter rose 75 percent year over year, as well as the South San Francisco, Calif.-based company's initial public offering earlier this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.